Navigation Links
New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective,Relative to Other Interferon Therapies for Multiple Sclerosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 13, 2007 - Biogen Idec Inc. (NASDAQ: BIIB) announced today that one-year data presented at the Academy of Managed Care Pharmacy's (AMCP) 2007 Annual Meeting show that AVONEX(R) (Interferon beta-1a) is a cost-effective therapy in multiple sclerosis (MS) when compared to other interferon beta treatments. Using a comprehensive analysis of medical and pharmacy costs, the results of the research concluded that patients treated with AVONEX, the most prescribed MS therapy worldwide, have the lowest total one-year cost to a health plan when compared to other interferon beta treatments.

Researchers analyzed 10,622 patients over one year to assess how demographic, administrative and clinical variables affect MS costs and utilization patterns and to examine the economic impact of treating MS. The independent data contained in Multiple Sclerosis Benchmarks(TM)(1), the retrospective, claims-based, observational study, showed that patients treated with AVONEX had the lowest average one-year cost compared to patients receiving other interferon beta treatments. It has been estimated that the total annual economic burden of MS in the United States exceeds $6.8 billion with a lifetime cost of $2.2 million per patient.(2)

"MS is a disease that can have an impact beyond its debilitating effect on patients," said Michael Pollock, Vice President, Global Health Economics, Biogen Idec. "Cost-effectiveness is an increasingly important factor in treating chronic diseases like MS. This study shows that in addition to its clinical impact, AVONEX can also help to substantially reduce the cost of care for patients living with this disease, when compared to other interferon beta treatments."

The MS Benchmarks analysis showed the total costs over one-year to MS patients on interferon beta therapy were: AVONEX, $19,896.15; Rebif(R) (Interferon beta-1a) sc, $22,207.85; and Betaseron(R) (Inter feron beta-1b), $21,073.33.

In addition, AVONEX patients were more likely to refill their prescriptions (avg.9.6/yr vs. 8.1 and 8.2/yr for other interferon beta therapies) and were less likely to use certain concomitant medications. Over the one-year period, use of disease-modifying therapies (interferon beta and glatiramer acetate) was almost always observed as monotherapy, reflecting little evidence of combination use or switching between products.

Additionally, according to data from the Quality Assessment of Multiple Sclerosis Therapy (QUASIMS) study presented at the AMCP Conference, patients do not derive additional clinical benefit from switching among interferon beta therapies. QUASIMS, an open-label, retrospective, observational study conducted in 14 countries, analyzed 7,156 MS patients who had received two years of uninterrupted therapy with interferon beta as initial therapy or follow-up therapy.

About AVONEX

AVONEX is the most prescribed treatment for relapsing forms of MS worldwide, with more than 130,000 patients on therapy. It was launched in the U.S. in 1996 and later in Europe for the treatment of relapsing forms of MS to slow the progression of disability and reduce relapses. AVONEX is marketed internationally in more than 90 countries. AVONEX was the first treatment approved for patients who have their first clinical MS attack and have a brain MRI scan consistent with MS; this use was approved in Europe in 2002 and in the U.S. in 2003. The most common side effects associated with AVONEX multiple sclerosis treatment are flu-like symptoms, including myalgia, fever, fatigue, headache, chills, nausea, vomiting, pain and asthenia.

AVONEX should be used with caution in patients with depression or other mood disorders and in patients with seizure disorders. AVONEX should not be used by pregnant women. Patients with cardiac disease should be closely monitored. Patients should also be monitored for signs of hepatic injury . Routine periodic blood chemistry and hematology tests are recommended during treatment with AVONEX. Rare cases of anaphylaxis have been reported. Please see complete prescribing information available at www.AVONEX.com.

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com. # # #

(1) "Multiple Sclerosis Benchmarks" is a trademark of Managed Care Measures, LLC.

(2) Coyle PK, Hartung HP. Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose-and frequency-dependent effects on clinical response. Multiple Sclerosis. 2002: 8:2-9.

Contact

Biogen Idec
Media Contact:
Amy Brockelman, 617-914-6524
Associate Director, Public Affairs
or
Investment Community Contact:
Eric Hoffman, 617-679-2812
Associate Director, Investor Relations


'"/>




Related medicine technology :

1. Acuity One-Year Findings Meet All Primary Endpoints in Favor of Angiomax (Bivalirudin) Alone Treatment Group
2. First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):